CaPtivantTM calcium phosphate nanoparticle technology should not be confused with the commercially available natural calcium phosphate mineral that has been in use in human vaccines in Europe since 1960s. Other than being a similar (not identical) chemical compound and equally safe for human vaccines, our CaP nanoparticle technology significantly differs from the commercial calcium phosphate with respect to morphology, physicochemical properties, and also mechanisms of adjuvant action in vaccines.
Unlike commercial calcium phosphate, alum, and various other adjuvants in development, CaPtiVaxTM exhibits properties that appear ideal for development of new vaccines or enhancing immune response to licensed vaccines:
Induces systemic and mucosal immune response by injection or mucosal administration
Induces higher antigen-specific humoral response than alum or lipid-based adjuvants in most cases
Stimulate both Th1- and Th2-type immune responses
Induces strong antigen-specific cytotoxic T lymphocyte (CTL) activation
Indicates potential for developing not only prophylactic but also therapeutic vaccines
Allows formulation of vaccines as stable dry powder
Does not stimulate IgE or generate local inflammatory reactions
Can also act as a depot for sustained release of Ag and enhances leucocyte recruitment and phagocytic activity of macrophages.
Demonstrates dose sparing properties often leading to the use of lower vaccine dosage while offering improved safety profiles.
CaPtivate's CaP Nanoparticles
Commercial Calcium Phosphate
initially developed by Pasteur Institute in France
Why Consider CaPtivantTM in Vaccines Development ?
Contains all GRAS components, is non-toxic, biodegradable, and biocompatible
Acute toxicity studies in Guinea pigs; no toxicity by injection routes, pulmonary, intranasal, or oral administration.
Safety and toxicity study in Phase I human clinical trial completed; no toxicity by injection
It is manufactured using cost-effective, standardized, high-yield, scalable, and flexible processes to produce particles in less than 100 nm to micrometer ranges
Process has been scaled up under cGMP
Is stable for many years when stored at room temperature
Can be freeze-dried into free-flowing uniform powder which is non-hygroscopic and stable for many years at room temperature
Vaccines formulated with CaP remain stable when exposed to freeze/thaw conditions
Large pre-clinical portfolio exists to demonstrate the safety and efficacy in human and veterinary vaccines
Is considered a natural preservative which enhances vaccine stability
Contains dose-sparing properties as in-vivo studies indicate that lower antigen doses will be required to achieve desired level of immunity
Demonstrates synergistic effects with other adjuvants
Vaccines containing CaP should face minimum regulatory challenges going into clinical trials
